Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 375 participants.
Also called NCT06272487
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 375 participants
- Sponsor
- Registry
-
NCT06272487
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Canada, Puerto Rico, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06272487. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-29 (actual); primary completion 2025-06-19 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
- Acronym
- KARDIA-3
- Condition
- High Cardiovascular Risk
- Condition
- Hypertension
- Intervention (Drug)
- Zilebesiran
- Intervention (Drug)
- Placebo
- Lead sponsor
- Alnylam Pharmaceuticals
Record details
- Record id
cardio:ct-nct06272487- Content hash
9e370ffa6cb0522a9d89a207cb476fa37996cfd9edfb71417d3268b55281925f